Clinical outcomes and neuroendocrine features of transformed versus primary small-cell lung cancer
Open Access
- 13 August 2025
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 207, 108714
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapyEuropean Journal of Cancer, 2024
- A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survivalLung Cancer, 2022
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung CancerJAMA, 2022
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialThe Lancet, 2019
- Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological MalignanciesCancer Cell, 2019
- A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic CharacteristicsJournal of Thoracic Oncology, 2019
- Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?Lung Cancer, 2011
- Predictive and prognostic factors in small cell lung cancer: current statusLung Cancer, 2000
- Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapyCancer, 1998
- SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCERThe Lancet, 1982